SC 52608

a superoxide dismutase mimetic; a synthetic Mn-based macrocyclic compound; structure given in first source

Also Known As:

MnPAM cpd; SC-52608; manganese(II) (1,4,7,10,13-pentaazacyclopentadecane)dichloride; Manganese, dichloro(1,4,7,10,13-pentaazacyclopentadecane-N1,N4,N7,N10,N13)-, (PB-7-11-22222)-

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - SC 52608: 2

Related Diseases

1.	Ischemia 09/01/1994 - "SC-52608 or the inactive analog SC-54385 was administered as four doses of 4 mg/kg i.v. Drug, inactive analog or vehicle was administered 30 and 15 min before ischemia and 15 min and immediately before reperfusion. " 08/01/1994 - "The hemodynamic, biochemical, morphological, as well as the antimyosin binding data, demonstrate that pretreatment with SC-52608 protects the myocardium from damage associated with global ischemia and reperfusion. " 08/01/1994 - "Protective effects of the SOD-mimetic SC-52608 against ischemia/reperfusion damage in the rabbit isolated heart."
2.	Reperfusion Injury 08/01/1994 - "Protective effects of the SOD-mimetic SC-52608 against ischemia/reperfusion damage in the rabbit isolated heart." 08/01/1994 - "An experimental model of myocardial ischemia/reperfusion injury was used to assess the cardioprotective effects of SC-52608, a low molecular weight superoxide dismutase mimetic. "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 08/01/1994 - "An experimental model of myocardial ischemia/reperfusion injury was used to assess the cardioprotective effects of SC-52608, a low molecular weight superoxide dismutase mimetic. "
4.	Myocardial Infarction 09/01/1994 - "Myocardial infarct sizes (% of area at risk of infarct) were 44.2 +/- 5.6%, 25.7 +/- 4.3% and 35.1 +/- 4.9% in control, SC-52608-treated and SC-54385-treated animals, respectively (P < .05 control vs. SC-52608-treated). "
5.	Infarction (Infarctions) 09/01/1994 - "Myocardial infarct sizes (% of area at risk of infarct) were 44.2 +/- 5.6%, 25.7 +/- 4.3% and 35.1 +/- 4.9% in control, SC-52608-treated and SC-54385-treated animals, respectively (P < .05 control vs. SC-52608-treated). "

Related Drugs and Biologics

1.	Superoxide Dismutase